Document is current
Any future updates will be listed below
-
Authors
Valle, Irene
Grinda, Thomas
Antonuzzo, Lorenzo
Pistilli, Barbara
- License Information
-
More Information
Article History
Received: 29 June 2025
Accepted: 7 September 2025
First Online: 29 September 2025
Competing interests
: I.V. declares no competing interests. T.G. reports having received travel support from AstraZeneca, Gilead, and Pfizer; has served in a consulting/advisory role for AstraZeneca and Cancerologie-Pratique; and has received research funding from Amgen. L.A. reports relationships with Amgen, Roche, AstraZeneca, and Novartis involving royalties, and has served in an advisory role for Merck Serono. B.P. has received consulting fees (institutional) from AstraZeneca, Seagen, Gilead, Novartis, Lilly, MSD, and Pierre Fabre; personal consulting fees from Pierre Fabre and Daiichi-Sankyo; research funding (institutional) from AstraZeneca, Daiichi-Sankyo, Gilead, Seagen, and MSD; and travel support from AstraZeneca, Pierre Fabre, Lilly, Daiichi-Sankyo, and MSD.
